Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118372) titled 'Phase I clinical study on the safety and tolerability of GRA2405 Powder For Inhalation in healthy adults and patients with Chronic Obstructive Pulmonary Disease' on Feb. 4.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: No. 28, Qiaozhong Middle Road, Liwan District, Guangzhou
Condition:
chronic obstructive pulmonary disease
Intervention:
the experimental group:GRA2405 inhalation powder, specifications:(1) 1.5 mg GRA2405 per capsule
(2) 3 mg GRA2405 per capsule
SAD-1.5mg : single inhalation administration, 1.5 mg/capsule x 1 capsule
SAD-3mg : single inhalation administration, 3 mg/...